Geron Expands Workforce and Equity Awards to Innovate Blood Cancer Treatments

Geron Corporation Expands Workforce to Drive Innovation in Blood Cancer Treatment

Geron Corporation, a biopharmaceutical company headquartered in Foster City, California, takes a strategic step to bolster its workforce by granting equity awards to three newly hired employees. On January 17, 2025, Geron awards a total of 312,000 shares of common stock, which includes stock options for 208,000 shares at an exercise price of $2.89 per share, matching the closing price on the grant date. The stock options come with a ten-year term and a structured vesting schedule, where 12.5% of the options vest after six months of employment, followed by monthly vesting of the remaining shares over the next three and a half years. This approach not only incentivizes new talent but also aligns employees' interests with the company’s long-term goals.

In addition to stock options, Geron grants 104,000 shares in the form of restricted stock units (RSUs). These RSUs have a vesting schedule that allows for 25% to vest each year on the anniversary of the grant date. This dual approach of offering both stock options and RSUs reflects Geron's commitment to attracting top-tier talent, which is crucial as the company aims to enhance its research and development capabilities. The equity awards comply with Nasdaq Listing Rule 5635(c)(4) and follow the guidelines outlined in Geron’s 2018 Inducement Award Plan, ensuring that the awards are structured in accordance with regulatory requirements.

Geron’s focus on innovation in the treatment of blood cancers is exemplified by its development of RYTELO™ (imetelstat), a first-in-class telomerase inhibitor that has received approval in the U.S. for specific adult patients with lower-risk myelodysplastic syndromes (LR-MDS). The company is currently conducting a pivotal Phase 3 clinical trial for patients with JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF). By targeting telomerase activity, prevalent in malignant stem and progenitor cells, RYTELO™ aims to halt cell proliferation and promote cell death, addressing a critical need in the treatment landscape.

Geron’s recent hiring and equity awards signify a proactive approach to expanding its talent pool in a competitive biotechnology sector. As the company continues to innovate and advance its promising therapies, it emphasizes the importance of building a skilled workforce dedicated to transforming the treatment paradigm for blood cancer. For more information about Geron’s initiatives and progress, interested parties can visit their official website or LinkedIn page.